Shopping Cart (0)
My Account

 Shopping Cart
Conferences | Training Courses | Market Reports | Managed Events | Past Conferences | Update Me
SELECTBIO Conferences Translational Medicine Summit
Conferences  \  Translational Medicine Summit  \  Agenda  \  Andreas Weinhaeusel
RegisterLogin

Andreas Weinhaeusel's Biography


Andreas Weinhaeusel, Senior Scientist, Austrian Institute of Technology GmbH

AW by his profession is biotechnologist and associate professor for molecular biology at the University of Natural Resources and Applied Life Sciences, Vienna.
Working from 1995-2004 at the Children’s Cancer Research Institute, Vienna he is experienced in human molecular genetic diagnostics and specialized on diagnostic-testing of syndromal and hereditary neoplastic disease. In 2001 AW obtained the post-doctoral graduation “Specialist in Human Genetics”. Along with diagnostic testing of imprinting disorders he started methylation testing as well as autoantibody testing on protein-microarrays on cancerous disease. Since 2004 at the AIT- Austrian Institute of Technology he specialized on DNA-methylation- and protein-biomarker research.

Andreas Weinhaeusel Image

Development and Validation of DNA Methylation Biomarkers

Friday, 7 June 2013 at 09:00

Add to Calendar ▼2013-06-07 09:00:002013-06-07 10:00:00Europe/LondonDevelopment and Validation of DNA Methylation BiomarkersTranslational Medicine Summit in HamburgHamburgSELECTBIOenquiries@selectbiosciences.com

Elucidation of DNA methylation changes is of utmost interest for the development of biomarkers. Along the biomarker developmental chain upon discovery of candidate markers, confirmation and validation are indispensable steps. We have successfully established genome wide screening using Illumina’s bisulfite deamination based 450k human methylation arrays in combination with high throughput-methylation sensitive restriction enzyme (MSRE) coupled qPCR for validation. Therefore we conduct high-throughput analyses of 96 samples x 96 qPCR assays in a single run using 10ng of patient’s DNA. Results from high throughput MSRE-qPCR using were successfully used for efficient confirmation of several panels of 100-200 top-candidate markers and further validation of DNA methylation changes in cancerous and non-cancerous disease. Our established platform combining bisulfite deamination based genome-wide screening and high throughput MSRE -qPCR enables reliable and very efficient validation of DNA methylation markers. 

Add to Calendar ▼2013-06-06 00:00:002013-06-07 00:00:00Europe/LondonTranslational Medicine SummitTranslational Medicine Summit in HamburgHamburgSELECTBIOenquiries@selectbiosciences.com


Conference Sponsors